In the Claims

Please delete claims in Group 1 (1-5), of which Claims 1-5 and newly added claims 20 -21 have been allowed in the parent application Serial No. 09/918,696. Current pending claims are Claims 6 – 19:

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Original): An isolated adenoviral E1B-55K protein comprising a single amino acid mutation wherein said mutation is selected from the group consisting of amino acids at positions 240 or 260 of said protein.

7. (Original): An isolated adenoviral E1B-55K protein comprising a single amino acid mutation
wherein said mutation is at position 240 of said protein.

8. (Original): An isolated adenoviral E1B-55K protein comprising a single amino acid mutation wherein said mutation is at position 260 of said protein.

9. (Original): An isolated polynucleotide wherein said polynucleotide comprises mutated adenoviral DNA that encodes a E1B-55K protein, said protein comprising a single amino acid mutation which mutation substantially reduces the capacity of said protein to bind to the tumor suppressor, p53.

10. (Original): An isolated polynucleotide as described in claim 9, wherein said polynucleotide is RNA.

11. (Original): A method of treating cancer in a patient in need of said treatment, comprising administering to said patient a dose of a recombinant adenovirus, said adenovirus comprising a mutation in the E1B-55K gene that encodes a mutated E1B-55K protein comprising a single

amino acid mutation, said mutation substantially reducing the ability of said E1B-55K mutated protein to bind to the tumor suppressor p53, and allowing sufficient time for said adenovirus to infect said cancer, and repeating said treatment if desired.

12. (Original): A method as described in claim 11, further comprising administering said recombinant adenovirus with a chemotherapeutic.

13. (Original): A method as described in claim 12, wherein said adenovirus is selected from the group consisting of Onyx 051 or Onyx 053.

14. (Original): A method of treating cancer in a patient in need of said treatment, comprising administering to said patient a dose of an isolated polynucleotide wherein said polynucleotide comprises mutated adenoviral DNA that encodes an E1B-55K protein, said protein comprising a single amino acid mutation which mutation substantially reduces the capacity of said protein to bind to the tumor suppressor, p53, and repeating said treatment if desired.

15. (Original): A method of treating cancer as described in claim 14, wherein said polynucleotide is RNA.

16. (Original): A method of treating cancer as described in claim 15, wherein said polynucleotide encodes said E1B-55K protein and said protein comprises a mutation at position 240 of said protein.

17. (Original): A method of treating cancer as described in claim 15, wherein said polynucleotide encodes said E1B-55K protein and said protein comprises a mutation at position 260 of said protein.

18. (Original): A method as described in claims 16 or 17, further comprising administering said polynucleotide with a chemotherapeutic.

19. (Original): A method as described in claim 15, wherein said polynucleotide is administered with a liposome.

20. (Previously added – Canceled)

21. (Previously added – Canceled)

22. (Previously added – Canceled)

CLAIMS FOR DIVISIONAL APPLICATION

1. (Canceled)

2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Original): An isolated adenoviral E1B-55K protein comprising a single amino acid mutation wherein said mutation is selected from the group consisting of amino acids at positions 240 or 260 of said protein.

7. (Original): An isolated adenoviral E1B-55K protein comprising a single amino acid mutation wherein said mutation is at position 240 of said protein.

8. (Original): An isolated adenoviral E1B-55K protein comprising a single amino acid mutation wherein said mutation is at position 260 of said protein.

9. (Original): An isolated polynucleotide wherein said polynucleotide comprises mutated adenoviral DNA that encodes a E1B-55K protein, said protein comprising a single amino acid mutation which mutation substantially reduces the capacity of said protein to bind to the tumor suppressor, p53.

10. (Original): An isolated polynucleotide as described in claim 9, wherein said polynucleotide is RNA.

11. (Original): A method of treating cancer in a patient in need of said treatment, comprising administering to said patient a dose of a recombinant adenovirus, said adenovirus comprising a mutation in the E1B-55K gene that encodes a mutated E1B-55K protein comprising a single amino acid mutation, said mutation substantially reducing the ability of said E1B-55K mutated protein to bind to the tumor suppressor p53, and allowing sufficient time for said adenovirus to infect said cancer, and repeating said treatment if desired.

12. (Original): A method as described in claim 11, further comprising administering said recombinant adenovirus with a chemotherapeutic.

13. (Original): A method as described in claim 12, wherein said adenovirus is selected from the group consisting of Onyx 051 or Onyx 053.

14. (Original): A method of treating cancer in a patient in need of said treatment, comprising administering to said patient a dose of an isolated polynucleotide wherein said polynucleotide comprises mutated adenoviral DNA that encodes an E1B-55K protein, said protein comprising a single amino acid mutation which mutation substantially reduces the capacity of said protein to bind to the tumor suppressor, p53, and repeating said treatment if desired.

15. (Original): A method of treating cancer as described in claim 14, wherein said polynucleotide is RNA.

16. (Original): A method of treating cancer as described in claim 15, wherein said polynucleotide encodes said E1B-55K protein and said protein comprises a mutation at position 240 of said protein.

17. (Original): A method of treating cancer as described in claim 15, wherein said polynucleotide encodes said E1B-55K protein and said protein comprises a mutation at position 260 of said protein.

18. (Original): A method as described in claims 16 or 17, further comprising administering said polynucleotide with a chemotherapeutic.

19. (Original): A method as described in claim 15, wherein said polynucleotide is administered with a liposome.

20. Previously added – Canceled)

21. (Previously added – Canceled)

22. (Previously added – Canceled)